Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of a Novel Modified Release Formulation of Oxcarbazepine (OXC MR) vs an Immediate Release Oxcarbazepine (OXC IR) Product in Patients With Partial Epilepsy

NCT00391534 is registered in ClinicalTrials.gov with Desitin Arzneimittel GmbH as lead sponsor.

NCT NCT00391534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00391534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of a Novel Modified Release Formulation of Oxcarbazepine (OXC MR) vs an Immediate Release Oxcarbazepine (OXC IR) Product in Patients With Partial Epilepsy
Lead sponsor
Desitin Arzneimittel GmbH
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2006
Completion date
November 30, 2009
Enrollment
100 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

partial epilepsy